Your browser is no longer supported. Please, upgrade your browser.
MYOS MYOS RENS Technology Inc. daily Stock Chart
MYOS [NASD]
MYOS RENS Technology Inc.
Index- P/E- EPS (ttm)-1.16 Insider Own10.80% Shs Outstand5.36M Perf Week-17.87%
Market Cap16.51M Forward P/E- EPS next Y- Insider Trans6.31% Shs Float2.48M Perf Month105.33%
Income-4.90M PEG- EPS next Q- Inst Own2.70% Short Float1.21% Perf Quarter93.71%
Sales0.30M P/S55.03 EPS this Y-4.70% Inst Trans- Short Ratio0.08 Perf Half Y75.00%
Book/sh1.05 P/B2.93 EPS next Y- ROA-68.50% Target Price- Perf Year103.97%
Cash/sh0.54 P/C5.69 EPS next 5Y- ROE-86.90% 52W Range1.02 - 6.98 Perf YTD161.02%
Dividend- P/FCF- EPS past 5Y- ROI-120.60% 52W High-60.35% Beta0.60
Dividend %- Quick Ratio2.50 Sales past 5Y- Gross Margin-91.00% 52W Low171.32% ATR0.71
Employees9 Current Ratio4.10 Sales Q/Q8.30% Oper. Margin- RSI (14)52.84 Volatility20.61% 37.13%
OptionableNo Debt/Eq0.11 EPS Q/Q56.30% Profit Margin- Rel Volume0.49 Prev Close3.08
ShortableYes LT Debt/Eq0.00 EarningsFeb 13 Payout- Avg Volume397.64K Price2.77
Recom2.00 SMA2024.74% SMA5054.36% SMA20056.31% Volume63,390 Change-10.15%
Jan-11-17 04:46PM  MYOS RENS TECHNOLOGY INC. Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Other +424.62%
Dec-22-16 04:31PM  MYOS RENS TECHNOLOGY INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders
Nov-25-16 08:01AM  MYOS RENS TECHNOLOGY INC. Files SEC form 8-K, Entry into a Material Definitive Agreement +6.00%
Nov-22-16 01:04PM  MYOS RENS TECHNOLOGY INC. Financials
Nov-18-16 11:46AM  MYOS RENS Technology, Inc. :MYOS-US: Earnings Analysis: Q3, 2016 By the Numbers : November 18, 2016
Nov-14-16 04:13PM  MYOS RENS TECHNOLOGY INC. Files SEC form 10-Q, Quarterly Report +6.90%
Sep-29-16 08:00AM  MYOS RENS Announces Publication of Its Fortetropin(R) Human Clinical Trial Manuscript Marketwired -6.86%
Sep-07-16 12:32PM  MYOS RENS Technology Inc. Appoints Joseph Mannello as Interim Chief Executive Officer Marketwired
Aug-31-16 08:01AM  MYOS RENS TECHNOLOGY INC. Files SEC form 8-K, Change in Directors or Principal Officers
Aug-24-16 04:17PM  MYOS RENS TECHNOLOGY INC. Files SEC form 8-K, Change in Directors or Principal Officers, Other Events
Aug-12-16 08:34AM  MYOS RENS TECHNOLOGY INC. Files SEC form 10-Q, Quarterly Report
Aug-08-16 04:35PM  MYOS RENS TECHNOLOGY INC. Files SEC form 8-K, Change in Directors or Principal Officers
Jun-29-16 04:17PM  MYOS RENS TECHNOLOGY INC. Files SEC form 8-K, Change in Directors or Principal Officers +11.61%
Jun-22-16 11:58AM  MYOS RENS Technology, Inc. :MYOS-US: Earnings Analysis: Q1, 2016 By the Numbers : June 22, 2016 -9.09%
May-20-16 05:26PM  MYOS RENS TECHNOLOGY INC. Files SEC form 8-K, Changes in Registrant's Certifying Accountant
May-13-16 08:34AM  MYOS RENS TECHNOLOGY INC. Files SEC form 10-Q, Quarterly Report
Apr-22-16 03:00PM  MYOS Reports Positive Results From Fortetropin(R) Clinical Study Marketwired
Apr-11-16 08:51AM  MYOS RENS Technology, Inc. :MYOS-US: Earnings Analysis: Q4, 2015 By the Numbers
07:49AM  MYOS RENS Technology, Inc. :MYOS-US: Earnings Analysis: 2015 By the Numbers
Mar-30-16 05:53PM  MYOS RENS TECHNOLOGY INC. Files SEC form 10-K, Annual Report
Mar-23-16 05:21AM  MYOS Corporation Announces Corporate Name Change to MYOS RENS Technology Inc. at noodls -8.02%
Mar-22-16 04:33PM  MYOS RENS TECHNOLOGY INC. Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financ +11.31%
07:33AM  MYOS Corporation Announces Corporate Name Change to MYOS RENS Technology Inc. Marketwired
Mar-08-16 05:31PM  MYOS CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of Equity Securities, Cha
04:17PM  MYOS Corporation Announces Election of New Directors and Appointment of Ren Ren as Global Chairman Marketwired
Mar-04-16 08:30AM  MYOS Corporation Announces the Initial Closing of a Strategic Investment by RENS Technology Inc. Marketwired
Feb-04-16 05:21PM  MYOS CORP Files SEC form 8-K, Change in Directors or Principal Officers, Other Events
Dec-22-15 05:09PM  MYOS CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation o
Dec-21-15 04:32PM  MYOS CORP Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Submission of Matters
Dec-17-15 01:55PM  Why Are These Stocks Gaining Ground on Thursday? at Insider Monkey +56.82%
11:00AM  4 Stocks Under $10 That Need To Be Watched Today Accesswire
08:00AM  MYOS Corporation Announces Strategic Investment by RENS Technology Inc. Marketwired
Nov-30-15 05:21PM  MYOS CORP Files SEC form 8-K, Other Events
Nov-16-15 05:15PM  MYOS CORP Files SEC form 10-Q, Quarterly Report +56.98%
Nov-03-15 12:08PM  MYOS Corp. Value Analysis (NASDAQ:MYOS) : November 3, 2015 -5.54%
Oct-26-15 07:35AM  Maintaining Muscle Linked to Preserving Healthy Brain Tissue Marketwired
Oct-19-15 07:35AM  MYOS' Proprietary Muscle Building Technology Fortetropin: Foundation for New Dietary Recommendations Marketwired +6.55%
Oct-02-15 10:53AM  MYOS Corp. Earnings Q2, 2015 +9.27%
Oct-01-15 08:00AM  Cryoport Appoints Robert Hariri, MD, PhD to its Board of Directors PR Newswire +16.79%
Aug-20-15 04:17PM  MYOS CORP Files SEC form 8-K, Change in Directors or Principal Officers -11.73%
Aug-16-15 08:12PM  10-Q for MYOS Corp. at Company Spotlight
Aug-14-15 06:14PM  MYOS CORP Files SEC form 10-Q, Quarterly Report
04:45PM  MYOS Corporation to Host Conference Call to Discuss Management Highlights Marketwired
Jul-22-15 07:35AM  MYOS Corporation Launches Optimized Re Muscle Health(TM) Website and HealthTrac App Marketwired
Jun-24-15 07:35AM  MYOS Corporation Issues Letter to Shareholders Highlighting Key Accomplishments Marketwired
Jun-11-15 07:35AM  MYOS Corporation Publishes Research Article on the Impact of Fertility on the Chicken Egg Yolk Proteome in Peer-Reviewed Journal Marketwired
May-28-15 07:35AM  MYOS Corporation Receives Health Canada Approval of Proprietary Ingredient Fortetropin(R) Marketwired +20.97%
May-26-15 07:35AM  MYOS Corporation Initiates Marketing Plan for Re Muscle Health(TM) Products Marketwired -9.93%
May-19-15 08:22AM  MYOS CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Material Modification to Rights of Security -17.89%
07:35AM  Astronaut Buzz Aldrin Relies on Re Muscle Health(TM) Products to Help Rebuild, Rejuvenate and Maintain Lean Muscle Marketwired
May-17-15 08:11PM  10-Q for MYOS Corp. at Company Spotlight
May-14-15 08:02AM  MYOS CORP Files SEC form 10-Q, Quarterly Report -8.67%
07:07AM  Q1 2015 MYOS Corp Earnings Release - Before Market Open
May-12-15 07:35AM  MYOS Corporation to Host Conference Call to Discuss Quarterly Update and Management Highlights Marketwired
May-11-15 07:35AM  MYOS Corporation Initiates Clinical Study on Fortetropin(R) Dose Response Marketwired +40.50%
Apr-29-15 08:15PM  10-K for MYOS Corp. at Company Spotlight
Mar-30-15 07:59AM  MYOS Corporation Announces the Re Muscle Health(TM) Series Powered by Fortetropin(R) at noodls
07:35AM  MYOS Corporation Announces the Re Muscle Health(TM) Series Powered by Fortetropin(R) Marketwired
Mar-27-15 04:59PM  MYOS CORP Files SEC form 10-K, Annual Report
04:57PM  MYOS Corporation to Host Conference Call to Discuss Quarterly Update and Management Highlights at noodls
04:35PM  MYOS Corporation to Host Conference Call to Discuss Quarterly Update and Management Highlights Marketwired
Mar-06-15 08:36AM  iHeart Radio's "HealthTech Talk" Show to Feature MYOS Corporation's Ingredient Fortetropin(TM) in Exclusive Interview With Company Chairman at noodls
07:15AM  iHeart Radio's "HealthTech Talk" Show to Feature MYOS Corporation's Ingredient Fortetropin(TM) in Exclusive Interview With Company Chairman Marketwired
Feb-23-15 08:27AM  MYOS Corporation to Present Mechanism of Action Data at the Experimental Biology Conference at noodls
07:30AM  MYOS Corporation to Present Mechanism of Action Data at the Experimental Biology Conference Marketwired
Feb-12-15 07:15AM  Chairman Dr. Robert Hariri of MYOS Corporation to Be Interviewed Live on Clear Channel's "The Trader's Network Show" Marketwired
Feb-11-15 08:05AM  MYOS Corporation Research Selected to Be Presented at International Conference on Molecular and Cellular Biology Marketwired -9.84%
Jan-22-15 08:53AM  MYOS Corporation's Preclinical Study of Fortetropin's(TM) Mechanism of Action Demonstrate Regulatory Effects on Three Key Muscle Health Pathways at noodls
08:00AM  MYOS Corporation's Preclinical Study of Fortetropin's(TM) Mechanism of Action Demonstrate Regulatory Effects on Three Key Muscle Health Pathways Marketwired
Jan-07-15 07:05AM  MYOS Corporation to Present at the Eighth Annual OneMedForum Conference on January 13, 2015 Marketwired
Dec-23-14 04:35PM  MYOS CORP Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Submission of Matters EDGAR Online
Dec-01-14 04:11PM  MYOS CORP Files SEC form 8-K, Other Events EDGAR Online
Nov-19-14 05:27PM  MYOS CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Stateme EDGAR Online
Nov-18-14 09:25AM  MYOS Corporation Announces $1.81 Million Registered Direct Offering Marketwired
Nov-15-14 07:07PM  10-Q for MYOS Corp. Company Spotlight
Nov-14-14 04:27PM  MYOS CORP Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Stat EDGAR Online
10:30AM  MYOS Corporation Reports 2014 Third Quarter Results and Provides Business Update Marketwired
Nov-13-14 05:20PM  MYOS CORP Files SEC form 10-Q, Quarterly Report EDGAR Online
Nov-11-14 07:05AM  MYOS Corporation to Announce Third Quarter 2014 Financial Results and Host Conference Call on November 14, 2014 Marketwired
Nov-04-14 08:05AM  MYOS Corporation Announces Positive Safety Data Demonstrating Fortetropin's(TM) Lack of Adverse Effect on Serum Lipids and Cholesterol Levels Marketwired
Oct-30-14 07:35AM  MYOS Corporation Announces Statistically Significant Top-Line Clinical Data Demonstrating Fortetropin's(TM) Anti-Inflammatory BioTherapeutic Properties Marketwired
Oct-02-14 08:05AM  MYOS Corporation to Present Positive Clinical Data at 55th Annual Conference of the American College of Nutrition Marketwired
Sep-18-14 07:35AM  MYOS Corporation Announces Research Agreement With Human Metabolome Technologies America to Conduct Clinical Metabolomic Studies in Subjects Using Fortetropin(TM) Marketwired
Sep-04-14 07:35AM  MYOS Corporation to Present at the Rodman & Renshaw 16th Annual Global Investment Conference on September 10, 2014 Marketwired
Aug-14-14 04:26PM  MYOS CORP Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Stat EDGAR Online
08:16AM  MYOS CORP Files SEC form 10-Q, Quarterly Report EDGAR Online
06:45AM  MYOS Corporation Reports 2014 Second Quarter Results Marketwired
Aug-07-14 08:05AM  MYOS Corporation to Announce Second Quarter 2014 Financial Results on August 14, 2014 Marketwired
Aug-06-14 08:05AM  MYOS Corporation Reports Additional Clinical Data on the Impact of Fortetropin on Lean Body Mass, Fat Mass and Muscle Size in Male Subjects Marketwired
Jul-30-14 08:04AM  MYOS Corporation Announces Appointment of Douglas Weekes as Chief Commercial Officer Marketwired
Jul-25-14 08:05AM  MYOS Corporation Extends Manufacturing and Supply Agreement for Fortetropin Marketwired
Jul-24-14 04:35PM  MYOS CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exhibits EDGAR Online
08:21AM  MYOS receives patent allowance in U.S. at theflyonthewall.com
08:05AM  MYOS Corporation Receives Notice of Allowance of U.S. Patent Application for Proprietary Manufacturing Methods of Fortetropin GlobeNewswire
Jul-22-14 08:45AM  MYOS Corp. Tackles Muscles Health at Seeking Alpha
08:11AM  MYOS reports positive top-line clinical study results for Fortetropin at theflyonthewall.com
08:05AM  MYOS Corporation Reports Positive Top-Line Clinical Study Results of Fortetropin's Muscle Building Activity in Male Subjects Marketwired
Jul-17-14 07:08AM  MYOS announces agreement with Cloud Pharmaceuticals theflyonthewall.com
07:05AM  MYOS Corporation Announces Agreement With Cloud Pharmaceuticals, Inc. to Develop Small Molecules Targeting Sarcopenia and Cachexia Marketwired
Jul-15-14 04:32PM  MYOS CORP Files SEC form 8-K, Change in Directors or Principal Officers, Other Events, Financial Statements and Exhib EDGAR Online
MYOS RENS Technology Inc., a bionutrition and biotherapeutics company, focuses on the discovery, development, and commercialization of nutritional and therapeutic products for maintaining and improving the health and performance of muscle tissue. The company primarily focuses on developing the products that improve muscle health and function essential to the management of sarcopenia, cachexia, and degenerative muscle diseases, and as an adjunct to the treatment of obesity. Its products include Fortetropin, a dietary supplement that has been shown in clinical studies to temporarily decrease the levels of serum myostatin; and MYO-T12, a proprietary formula containing Fortetropin and other ingredients for the sports nutrition market. The company was formerly known as MYOS Corporation and changed its name to MYOS RENS Technology Inc. in March 2016. MYOS RENS Technology Inc. was founded in 2007 and is based in Cedar Knolls, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
LYU ZHENGGUANGDirectorDec 02Buy1.539311,424117,842Dec 09 01:39 PM
LYU ZHENGGUANGDirectorDec 01Buy1.4714,92321,998116,911Dec 09 01:39 PM
LYU ZHENGGUANGDirectorNov 30Buy1.4318,48326,431101,988Dec 09 01:39 PM